CERO CERo Therapeutics Holdings Company Short-Term Debt

cero.bio - graphic logo of issuer CERO

The asset value of CERo Therapeutics (CERO) tracked on this chart is currently at 0.00. The development of this micro-cap business is complicated by a liquidity shortage and manufacturing challenges. Meanwhile, CERo Therapeutics (CERO) relies on T-cell innovations that enable the immune system to destroy neoplasms. This unique method of reprogramming the body for specific types of tumors creates opportunities for high-cost personalized treatment due to low demand elasticity.

CERO CERo Therapeutics Holdings Inc. Short-Term Debt (02/21/2024 - 11/08/2025)

Analytical breakdowns and data insights for company CERo Therapeutics Holdings, Inc. (CERO)

- current quotes and average value forecast:
Price Chart CERo Therapeutics Holdings Inc.|CERO - Average Forecast Price
- market capitalization data:
Market Value CERo Therapeutics Holdings|CERO - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share CERo Therapeutics|CERO - Total Stockholders' Equity|Market Capitalization to Book Value Ratio cero.bio|CERO - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio CERo Therapeutics|CERO - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio CERo Therapeutics Holdings Inc.|CERO - Aggregate Debt Obligations|Debts to Book Capitalization CERo Therapeutics Holdings|CERO - Company Long-Term Liabilities|Company Short-Term Debts CERo Therapeutics|Quick Liquidity cero.bio
- earnings and multiples data:
CERO - Company Net Income
General company analysis:cero.bio (CERO)
Flagship merchandise of CERo Therapeutics

The intellectual capital of CERo Therapeutics (CERO) in cell engineering provides long-term potential for the monetization of anti-tumor patents. By analyzing the volume of current liabilities, an investor assesses the amount of urgent payments due within a year, which allows for the determination of liquidity risk and the stability of the company's financial model in the face of operational costs for therapy development.

Competitor analysis

LEGN - Company Short-Term Debt|Short-Term Debt Sana Biotechnology Inc|Autolus Pharma (AUTL) - Company Short-Term Debt|ALLO (Allogene Corp) - Company Short-Term Debt|Company Short-Term Debt Cartesian Therapeutics|Short-Term Debt Cellectis Biotherapeutics CLLS|Company Short-Term Debts CRBU|Instil Bio Inc. (TIL) - Short-Term Indebtedness|Genenta Science - Company Current Liabilities|Century Tx (IPSC) - Short-Term Debt|JSPR: Company Current Liabilities|Company Short-Term Loans and Borrowings SNTI (Senti Biosciences, Inc.)|ADAP: Company Short-Term Debts|Company Current Liabilities Alaunos Therapeutics, Inc.|ACHL (Achilles Therapeutics PLC) - Company Short-Term Debts|Short-Term Debt CARGO Therapeutics, Inc CRGX|Company Short-Term Debt Poseida Therapeutics (PSTX)|Company Short-Term Debt TSVT (2seventybio.com)|Company Short-Term Debt Gracell Biotechnologies Inc. GRCL